

Juergen Braun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6777126/publications.pdf>

Version: 2024-02-01

571
papers

59,812
citations

910

119
h-index

1518

224
g-index

772
all docs

772
docs citations

772
times ranked

16915
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?" by Su et al. Annals of the Rheumatic Diseases, 2023, 82, e171-e171.	0.5	1
2	Correspondence on "Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial" by Molto et al. Annals of the Rheumatic Diseases, 2023, 82, e229-e229.	0.5	1
3	Response to: Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis"? by Siebert and Marzo-Ortega. Annals of the Rheumatic Diseases, 2023, 82, e186-e186.	0.5	3
4	Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52-Week, Randomized, Controlled Trial. Arthritis Care and Research, 2022, 74, 451-460.	1.5	10
5	Comment on "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry" by Gianfrancesco M et al. Annals of the Rheumatic Diseases, 2022, 81, e189-e189.	0.5	7
6	What's new on the sacroiliac joint ? Comment on: "Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease" Rheumatology, 2022, 61, 475-477.	0.9	4
7	Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Annals of the Rheumatic Diseases, 2022, 81, 41-47.	0.5	39
8	Successful Evaluation of Spinal Mobility Measurements With the Epionics SPINE Device in Patients With Axial Spondyloarthritis Compared to Controls. Journal of Rheumatology, 2022, 49, 44-52.	1.0	8
9	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. Rheumatology, 2022, 61, 2054-2062.	0.9	4
10	No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis"? Annals of the Rheumatic Diseases, 2022, 81, 466-468.	0.5	31
11	Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning. Annals of the Rheumatic Diseases, 2022, 81, 11-14.	0.5	11
12	Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study. Rheumatology, 2022, 61, 2875-2885.	0.9	3
13	Striking sex differences in magnetic resonance imaging findings in the sacroiliac joints in the population. Arthritis Research and Therapy, 2022, 24, 29.	1.6	13
14	Right ventricular remodelling in patients with significant tricuspid regurgitation undergoing tricuspid valve surgery. European Heart Journal Cardiovascular Imaging, 2022, 23, .	0.5	0
15	Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years. Rheumatology, 2022, 61, 4722-4730.	0.9	3
16	Monitoring of Disease Activity With a Smartphone App in Routine Clinical Care in Patients With Axial Spondyloarthritis. Journal of Rheumatology, 2022, 49, 878-884.	1.0	13
17	Effects of patient and disease characteristics on global functioning in patients with axial spondyloarthritis in routine care. Seminars in Arthritis and Rheumatism, 2022, 55, 152006.	1.6	7
18	Changes of immunosuppressive medication because of COVID-19 by patients with chronic inflammatory rheumatic diseases: anxiety was not a major driver.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0

#	ARTICLE	IF	CITATIONS
19	Response to: Correspondence on “No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post hoc analyses of psoriatic arthritis-related “physician-reported spondylitis”” by Braun and Landewé. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2022-222359.	0.5	2
20	The Efficacy of “Short-Term” Bridging Strategies With High- and “Low-Dose” Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A “Double-Blind”, Randomized, “Placebo-Controlled” Trial. <i>Arthritis and Rheumatology</i> , 2022, 74, 1628-1637.	2.9	9
21	High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis. <i>RMD Open</i> , 2022, 8, e002383.	1.8	12
22	Low-dose CT hounsfield units: a reliable methodology for assessing vertebral bone density in radiographic axial spondyloarthritis. <i>RMD Open</i> , 2022, 8, e002149.	1.8	6
23	Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis. <i>RMD Open</i> , 2022, 8, e002250.	1.8	9
24	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	1.5	43
25	Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. <i>Arthritis Care and Research</i> , 2021, 73, 289-295.	1.5	5
26	Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, “Placebo-Controlled” Phase III Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 110-120.	2.9	100
27	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. <i>Journal of Rheumatology</i> , 2021, 48, 188-197.	1.0	7
28	The efficacy of a nurse-led interventional program to improve the health of patients with axial spondyloarthritis. <i>Rheumatology</i> , 2021, 60, 487-488.	0.9	0
29	Which factors are associated with bone marrow oedema suspicious of axial spondyloarthritis as detected by MRI in the sacroiliac joints and the spine in the general population?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 469-474.	0.5	23
30	Which Magnetic Resonance Imaging Lesions in the Sacroiliac Joints Are Most Relevant for Diagnosing Axial Spondyloarthritis? A Prospective Study Comparing Rheumatologists’ Evaluations With Radiologists’ Findings. <i>Arthritis and Rheumatology</i> , 2021, 73, 800-805.	2.9	19
31	Dr. Kiltz, et al reply. <i>Journal of Rheumatology</i> , 2021, 48, 788.2-788.	1.0	0
32	Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110418.	1.2	9
33	Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study. <i>RMD Open</i> , 2021, 7, e001499.	1.8	8
34	Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response”. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e162-e162.	0.5	15
35	Treat-to-target in axial spondyloarthritis “ what about physical function and activity?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 565-576.	3.5	21
36	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. <i>Arthritis Research and Therapy</i> , 2021, 23, 231.	1.6	17

#	ARTICLE	IF	CITATIONS
37	Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination. <i>Zeitschrift Fur Rheumatologie</i> , 2021, 80, 33-48.	0.5	13
38	A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S). <i>Lung Cancer</i> , 2021, 161, 42-48.	0.9	3
39	Favourable outcome of planned pregnancies in systemic sclerosis patients during stable disease. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-7.	0.6	0
40	Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1. <i>BMC Musculoskeletal Disorders</i> , 2021, 22, 1037.	0.8	8
41	Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis. <i>Journal of Rheumatology</i> , 2020, 47, 35-41.	1.0	6
42	Nonsteroidal anti-inflammatory drugs and cardiovascular risk – a matter of indication. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 285-288.	1.6	41
43	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. <i>Lancet, The</i> , 2020, 395, 53-64.	6.3	138
44	Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 186-192.	0.5	79
45	Do NSAIDs affect radiographic progression in axial SpA?. <i>Nature Reviews Rheumatology</i> , 2020, 16, 9-10.	3.5	2
46	ASAS Health Index: The “All in One” for Spondyloarthritis Evaluation?. <i>Journal of Rheumatology</i> , 2020, 47, 1457-1460.	1.0	11
47	Functional MR imaging beyond structure and inflammation – radiographic axial spondyloarthritis is associated with proteoglycan depletion of the lumbar spine. <i>Arthritis Research and Therapy</i> , 2020, 22, 219.	1.6	4
48	Facet joint ankylosis in r-axSpA: detection and 2-year progression on whole spine low-dose CT and comparison with syndesmophyte progression. <i>Rheumatology</i> , 2020, 59, 3776-3783.	0.9	19
49	Response to: “Frequency of MRI changes suggestive of axial spondyloarthritis in the axial in a large population-based cohort of individuals aged <45 years” by Parperis. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2019-216798.	0.5	0
50	Early recognition of patients with axial spondyloarthritis – evaluation of referral strategies in primary care. <i>Rheumatology</i> , 2020, 59, 3845-3852.	0.9	19
51	Diagnostic capability of contrast-enhanced pelvic girdle magnetic resonance imaging in polymyalgia rheumatica. <i>Rheumatology</i> , 2020, 59, 2864-2871.	0.9	13
52	Assessments of Functioning in Patients With Axial Spondyloarthritis. <i>Journal of Rheumatic Diseases</i> , 2020, 27, 22.	0.4	14
53	Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 193-201.	0.5	59
54	OP0086 – THE DEGREE OF BONE MARROW EDEMA AS DETECTED BY MAGNETIC RESONANCE IMAGING IN THE SACROILIAC JOINTS AND THE SPINE SUSPICIOUS OF AXIAL SPONDYLOARTHRITIS IN THE GENERAL POPULATION IS ASSOCIATED WITH DIFFERENT FACTORS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 57-57.	0.5	5

#	ARTICLE	IF	CITATIONS
55	Rheumatologische Versorgung im Rheumazentrum Ruhrgebiet. , 2020, , 307-322.		0
56	Long-term follow-up of thoracoscopic ablation for long-standing persistent atrial fibrillation. European Heart Journal, 2020, 41, .	1.0	0
57	Spinal mobility in the cervical and lumbar spine correlates with magnetic resonance imaging findings for inflammatory and structural changes in patients with active ankylosing spondylitis. Clinical and Experimental Rheumatology, 2020, 38, 467-471.	0.4	4
58	Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology, 2019, 58, 388-400.	0.9	93
59	Observation by Magnetic Resonance Imaging of Sacroiliac Joint Ankylosis in Young Spondyloarthritis Patients Receiving Biologic Therapy: Comment on the Article by Bray et al. Arthritis and Rheumatology, 2019, 71, 2128-2129.	2.9	0
60	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Annals of the Rheumatic Diseases, 2019, 78, 1550-1558.	0.5	171
61	Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. PLoS ONE, 2019, 14, e0221823.	1.1	22
62	What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis. Annals of the Rheumatic Diseases, 2019, 78, 1220-1225.	0.5	35
63	Spinal radiographic progression over 2Âyears in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Research and Therapy, 2019, 21, 142.	1.6	31
64	Using combinations of biomarkers to understand inflammation and bone formation in axial spondyloarthritis â€“ is anything better than CRP?. Rheumatology, 2019, 58, 1517-1519.	0.9	2
65	Detection of Erosions in Sacroiliac Joints of Patients with Axial Spondyloarthritis Using the Magnetic Resonance Imaging Volumetric Interpolated Breath-hold Examination. Journal of Rheumatology, 2019, 46, 1445-1449.	1.0	41
66	Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open, 2019, 5, e001005.	1.8	70
67	Three Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 258-270.	2.9	237
68	Active and chronic sacroiliitis, spondylitis and enthesitis, How specific are imaging findings for axial spondyloarthritis?. Rheumatology, 2019, 58, 1321-1324.	0.9	12
69	Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology, 2019, 58, 859-868.	0.9	108
70	Sensitivity and Specificity of Autoantibodies Against CD 74 in Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 729-735.	2.9	31
71	Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases, 2018, 77, 699-705.	0.5	98
72	Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingnessâ€toâ€Pay Approach. Arthritis Care and Research, 2018, 70, 608-616.	1.5	1

#	ARTICLE	IF	CITATIONS
73	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
74	Dual-phase hybrid ¹⁸ F-fluoride Positron emission tomography/MRI in ankylosing spondylitis: Investigating the link between MRI bone changes, regional hyperaemia and increased osteoblastic activity. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 313-319.	0.9	18
75	Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, 1541-1547.	0.9	52
76	Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 293-299.	0.5	71
77	Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 371-377.	0.5	48
78	Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies. <i>RMD Open</i> , 2018, 4, e000749.	1.8	30
79	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. <i>RMD Open</i> , 2018, 4, e000825.	1.8	45
80	Axial spondyloarthritis including ankylosing spondylitis. <i>Rheumatology</i> , 2018, 57, vi1-vi3.	0.9	17
81	Learning from the youngsters: ixekizumab in active ankylosing spondylitis. <i>Lancet</i> , The, 2018, 392, 2415-2416.	6.3	3
82	Discontinuing tumour necrosis factor inhibitors in non-radiographic axial spondyloarthritis. <i>Lancet</i> , The, 2018, 392, 98-100.	6.3	3
83	2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1251-1260.	0.5	450
84	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1311-1317.	0.5	85
85	Prevalence of inflammatory and chronic changes suggestive of axial spondyloarthritis in magnetic resonance images of the axial skeleton in individuals <45 years in the general population as part of a large community study (SHIP)., 2018, , .		1
86	Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study. <i>RMD Open</i> , 2018, 4, e000659.	1.8	9
87	Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 50-55.	0.4	69
88	Imaging of axial spondyloarthritis. New aspects and differential diagnoses. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 35-42.	0.4	7
89	The role of 18F-FDG positron emission tomography for the diagnosis of vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 114, 108-114.	0.4	3
90	The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 289-302.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1070-1077.	0.5	213
92	2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 978-991.	0.5	1,220
93	Treat-to-target (T2T) recommendations for gout. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 632-638.	0.5	118
94	Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000396.	1.8	99
95	Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000397.	1.8	69
96	Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. <i>Rheumatology</i> , 2017, 56, 1498-1509.	0.9	78
97	Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2017, 69, 1590-1598.	1.5	28
98	Effect of certolizumab pegol over 96-weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis. <i>RMD Open</i> , 2017, 3, e000430.	1.8	28
99	Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis – the TryCort study. <i>Arthritis Research and Therapy</i> , 2017, 19, 73.	1.6	7
100	Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 346-354.	0.5	204
101	How should axial spondyloarthritis be diagnosed?. <i>Nature Reviews Rheumatology</i> , 2017, 13, 264-266.	3.5	2
102	Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. <i>Rheumatology</i> , 2017, 56, 95-102.	0.9	58
103	Biologic Therapy for HLA-B27-associated Ocular Disorders. <i>Ocular Immunology and Inflammation</i> , 2017, 25, 169-178.	1.0	17
104	Low Rate of Progression to Ankylosing Spondylitis Among Patients With Presumed Nonradiographic Axial Spondyloarthritis: Comment on the Article by Wang et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 676-677.	2.9	3
105	Chronic but not inflammatory changes at the Achilles™ tendon differentiate patients with peripheral spondyloarthritis from other diagnoses – Results from a prospective clinical trial. <i>RMD Open</i> , 2017, 3, e000541.	1.8	14
106	Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. <i>Deutsches Ar&#x0308;rzteblatt International</i> , 2017, 114, 197-203.	0.6	34
107	Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 189-211.		0
108	Response to methotrexate predicts long-term mortality of patients with rheumatoid arthritis independent of the degree of response: results of a re-evaluation 30 years after baseline. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 384-389.	0.4	2

#	ARTICLE	IF	CITATIONS
109	Causes of pain in patients with axial spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 107, 102-107.	0.4	10
110	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2114-2118.	0.5	103
111	Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. <i>Arthritis Research and Therapy</i> , 2016, 18, 304.	1.6	30
112	Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. <i>RMD Open</i> , 2016, 2, e000272.	1.8	4
113	Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. <i>Arthritis Research and Therapy</i> , 2016, 18, 25.	1.6	120
114	Imaging Scoring Methods in Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 663-678.	0.8	17
115	Which aspects of health are most important for patients with spondyloarthritis? A Best Worst Scaling based on the ASAS Health Index. <i>Rheumatology</i> , 2016, 55, 1771-1776.	0.9	25
116	Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab. <i>Journal of Rheumatology</i> , 2016, 43, 1704-1712.	1.0	34
117	New targets in psoriatic arthritis. <i>Rheumatology</i> , 2016, 55, ii30-ii37.	0.9	14
118	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF- α Inhibitors for Up to 10 Years. <i>Journal of Rheumatology</i> , 2016, 43, 2142-2148.	1.0	38
119	Quantification of Bone Marrow Edema by Magnetic Resonance Imaging Only Marginally Reflects Clinical Neck Pain Evaluation in Rheumatoid Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 2131-2135.	1.0	5
120	Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 2120-2130.	1.0	33
121	Response to: α -Infliximab and CT-P13 immunogenicity assessment in PLANETAS and PLANETRA main and extension studies: utility of laboratory methods description α ™ by Francesca Meacci et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e63-e63.	0.5	0
122	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. <i>RMD Open</i> , 2016, 2, e000311.	1.8	31
123	Outcome of stand-alone thoracoscopic epicardial left atrial posterior box isolation with bipolar radiofrequency energy for longstanding persistent atrial fibrillation. <i>Netherlands Heart Journal</i> , 2016, 24, 143-151.	0.3	7
124	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1958-1963.	0.5	383
125	Secukinumab (AIN457) in the treatment of ankylosing spondylitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 711-722.	1.4	22
126	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.5	53

#	ARTICLE	IF	CITATIONS
127	The term "non-radiographic axial spondyloarthritis"™ is much more important to classify than to diagnose patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 791-794.	0.5	105
128	Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. <i>Journal of Rheumatology</i> , 2016, 43, 901-906.	1.0	13
129	Response to methotrexate predicts long-term patient-related outcomes in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2016, 35, 1123-1127.	1.0	4
130	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 499-510.	0.5	743
131	MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1486-1493.	0.5	103
132	Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1328-1335.	0.5	81
133	Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 408-412.	0.5	63
134	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1438-1443.	0.5	163
135	Dopaminergic Neurodegeneration in the Mouse Is Associated with Decrease of Viscoelasticity of Substantia Nigra Tissue. <i>PLoS ONE</i> , 2016, 11, e0161179.	1.1	30
136	PROMs for Spondyloarthritis. , 2016, , 121-147.		0
137	Non-radiographic axial spondyloarthritis: a classification or a diagnosis?. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S5-6.	0.4	6
138	Axial spondyloarthritis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15013.	18.1	135
139	Do patients with ankylosing spondylitis adapt to their disease? Evidence from a 'then-test' in patients treated with TNF inhibitors. <i>RMD Open</i> , 2015, 1, e000164-e000164.	1.8	1
140	Longitudinal Analyses of Presenteeism and Its Role as a Predictor of Sick Leave in Patients With Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2015, 67, 1578-1585.	1.5	17
141	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2015, 67, 2369-2375.	2.9	28
142	Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 935-946.	1.3	13
143	Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?: Table 1. <i>RMD Open</i> , 2015, 1, e000053.	1.8	83
144	Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. <i>New England Journal of Medicine</i> , 2015, 373, 2534-2548.	13.9	803

#	ARTICLE	IF	CITATIONS
145	THU0233â€¦Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 281.1-281.	0.5	5
146	AB0743â€¦Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1147-1147.	0.5	3
147	Effect of Certolizumab Pegol Over Ninetyâ€¦Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial. <i>Arthritis and Rheumatology</i> , 2015, 67, 668-677.	2.9	49
148	Golimumab administered subcutaneously every 4â€¦weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 757-761.	0.5	92
149	Emerging drugs for the treatment of axial and peripheral spondyloarthritis. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 1-14.	1.0	40
150	Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. <i>Immunotherapy</i> , 2015, 7, 73-87.	1.0	14
151	Hybrid 18F-labeled Fluoride Positron Emission Tomography/Magnetic Resonance (MR) Imaging of the Sacroiliac Joints and the Spine in Patients with Axial Spondyloarthritis: A Pilot Study Exploring the Link of MR Bone Pathologies and Increased Osteoblastic Activity. <i>Journal of Rheumatology</i> , 2015, 42, 1631-1637.	1.0	48
152	Classification and Diagnosis of Axial Spondyloarthritis â€” What Is the Clinically Relevant Difference?. <i>Journal of Rheumatology</i> , 2015, 42, 31-38.	1.0	37
153	Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 830-835.	0.5	161
154	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 538-546.	0.5	75
155	Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1051-1057.	0.5	128
156	High Resolution Imaging of Viscoelastic Properties of Intracranial Tumours by Multi-Frequency Magnetic Resonance Elastography. <i>Clinical Neuroradiology</i> , 2015, 25, 371-378.	1.0	79
157	Imaging in spondyloarthritis. , 2015, , 960-969.		2
158	Periphere Spondyloarthritis. , 2015, , 1-6.		0
159	Radiologic damage at baseline predicts patient-related outcomes 18 years after the initiation of methotrexate therapy in patients with severe rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 611-6.	0.4	3
160	Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 344.	0.7	5
161	Assessment of spinal pain. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 875-887.	1.4	20
162	The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4â€¦years of the GO-RAISE trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1107-1113.	0.5	105

#	ARTICLE	IF	CITATIONS
163	Patient-Activated Three-Dimensional Multifrequency Magnetic Resonance Elastography for High-Resolution Mechanical Imaging of the Liver and Spleen. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2014, 186, 260-266.	0.7	15
164	Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1819-1825.	0.5	161
165	The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial. <i>Journal of Rheumatology</i> , 2014, 41, 1095-1103.	1.0	41
166	German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. <i>Rheumatology International</i> , 2014, 34, 1-9.	1.5	33
167	Clinician's Manual on Axial Spondyloarthritis. , 2014, , .		3
168	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 349-356.	0.5	308
169	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2137-2143.	0.5	62
170	Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 39-47.	0.5	378
171	Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 710-715.	0.5	238
172	Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 238-242.	0.5	65
173	Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 243-246.	0.5	83
174	Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. <i>Arthritis and Rheumatology</i> , 2014, 66, 2091-2102.	2.9	185
175	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.5	314
176	High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1079-1082.	0.5	72
177	The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns. <i>Arthritis and Rheumatology</i> , 2014, 66, 2649-2656.	2.9	81
178	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
179	Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 647-659.	1.9	22
180	Overview of Axial Spondyloarthritis. , 2014, , 5-16.		2

#	ARTICLE	IF	CITATIONS
181	Diagnosis of Axial Spondyloarthritis. , 2014, , 31-45.		3
182	Axiale Spondyloarthritis (einschließlich ankylosierender Spondylitis). , 2014, , 1-16.		0
183	Clinical Manifestations of Axial Spondyloarthritis. , 2014, , 17-29.		0
184	Imaging in Axial Spondyloarthritis. , 2014, , 47-58.		0
185	Management of Axial Spondyloarthritis. , 2014, , 59-96.		2
186	The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline. Clinical and Experimental Rheumatology, 2014, 32, 395-400.	0.4	6
187	The ASAS Health Index (ASAS HI) - a new tool to assess the health status of patients with spondyloarthritis. Clinical and Experimental Rheumatology, 2014, 32, S-105-8.	0.4	17
188	Opinion: Perspectives on imaging in axial spondyloarthritis. Nature Reviews Rheumatology, 2013, 9, 498-502.	3.5	17
189	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 382, 1705-1713.	6.3	518
190	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GERman SPondyloarthritis Inception Cohort (GESPIC). Annals of the Rheumatic Diseases, 2013, 72, 1430-1432.	0.5	67
191	Outcome assessment in axial spondyloarthritis-imaging techniques, their relation to outcomes and their use in clinical trials. Indian Journal of Rheumatology, 2013, 8, S38-S43.	0.2	1
192	Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Research and Therapy, 2013, 15, R67.	1.6	44
193	Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology, 2013, 52, 321-325.	0.9	28
194	Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis. Journal of Rheumatology, 2013, 40, 1557-1565.	1.0	55
195	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Annals of the Rheumatic Diseases, 2013, 72, 1605-1612.	0.5	531
196	Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy. Journal of Rheumatology, 2013, 40, 1891-1896.	1.0	17
197	Optimizing the identification of patients with axial spondyloarthritis in primary care—the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatology, 2013, 52, 1418-1424.	0.9	47
198	Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Annals of the Rheumatic Diseases, 2013, 72, 1104-1107.	0.5	18

#	ARTICLE	IF	CITATIONS
199	Long-term Efficacy of Adalimumab After Drug Withdrawal and Retreatment in Patients With Active Non-radiographically Evident Axial Spondyloarthritis Who Experience a Flare. <i>Arthritis and Rheumatism</i> , 2013, 65, 2211-2213.	6.7	45
200	Response to "Evidence in Support of the Validity of the TNF Brake Hypothesis" by Maksymowych. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, e32-e33.	0.5	4
201	One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 305-306.	0.5	47
202	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.5	114
203	OP0169...Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized, Double-blind, placebo-controlled, international study (align). <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 111.3-112.	0.5	21
204	OP0167...A randomized, double-blind, phase 1 study demonstrates equivalence in pharmacokinetics, safety, and efficacy of CT-P13 and infliximab in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 111.1-111.	0.5	10
205	Republished: The risks of smoking in patients with spondyloarthritides. <i>Postgraduate Medical Journal</i> , 2012, 88, 617-618.	0.9	3
206	First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Rheumatology</i> , 2012, 51, 1388-1396.	0.9	112
207	Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition. <i>Current Opinion in Rheumatology</i> , 2012, 24, 252-260.	2.0	30
208	Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. <i>Rheumatology</i> , 2012, 51, 1378-1387.	0.9	63
209	Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 674-680.	0.5	24
210	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, i2-i45.	0.5	71
211	The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1207-1211.	0.5	80
212	MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 2002-2005.	0.5	87
213	MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 369-373.	0.5	126
214	European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 4-12.	0.5	405
215	Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 878-884.	0.5	72
216	Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 661-667.	0.5	92

#	ARTICLE	IF	CITATIONS
217	Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. <i>Rheumatology</i> , 2012, 51, 1687-1696.	0.9	24
218	Clinical Efficacy of Etanercept Versus Sulfasalazine in Ankylosing Spondylitis Subjects with Peripheral Joint Involvement. <i>Journal of Rheumatology</i> , 2012, 39, 836-840.	1.0	25
219	Comparison of three methods for calculating the Bath Ankylosing Spondylitis Metrology Index in a randomized placebo-controlled study. <i>Arthritis Care and Research</i> , 2012, 64, 1919-1922.	1.5	19
220	Imaging in Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 513-522.	0.8	11
221	The risks of smoking in patients with spondyloarthritides. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 791-792.	0.5	15
222	Preface. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, xvii-xxi.	0.8	0
223	How Important is Early Therapy in Axial Spondyloarthritis?. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 635-642.	0.8	17
224	Inflammatory Back Pain. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 487-499.	0.8	7
225	ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1103-1104.	0.5	15
226	Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. <i>Rheumatology</i> , 2012, 51, 1894-1905.	0.9	32
227	Biologic Therapies for Spondyloarthritis: What Is New?. <i>Current Rheumatology Reports</i> , 2012, 14, 422-427.	2.1	35
228	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1616-1622.	0.5	286
229	Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?. <i>Arthritis Care and Research</i> , 2012, 64, 1415-1422.	1.5	270
230	The disease process in axial SpA: what can biomarkers tell us?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 8-10.	3.5	3
231	Classification, Diagnosis, and Referral of Patients with Axial Spondyloarthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 477-485.	0.8	21
232	Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1278-1288.	0.5	218
233	A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: A retrospective cohort study over six years. <i>Arthritis and Rheumatism</i> , 2012, 64, 1127-1133.	6.7	70
234	Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1388-1398.	6.7	384

#	ARTICLE	IF	CITATIONS
235	Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers: Example of etanercept in advanced ankylosing spondylitis. <i>Arthritis Care and Research</i> , 2012, 64, 290-294.	1.5	15
236	Axial spondyloarthritis: thoughts about nomenclature and treatment targets. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S132-5.	0.4	4
237	Gout: thoughts about a treat-to-target programme. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S142-4.	0.4	2
238	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, i2-i36.	0.5	287
239	Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1782-1787.	0.5	100
240	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 896-904.	0.5	831
241	Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 47-53.	0.5	589
242	2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 905-908.	0.5	365
243	Spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 825-842.	1.4	35
244	The Natural Course of Radiographic Progression in Ankylosing Spondylitis: Differences Between Genders and Appearance of Characteristic Radiographic Features. <i>Current Rheumatology Reports</i> , 2011, 13, 383-387.	2.1	46
245	Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 1543-1551.	6.7	125
246	Predicting the outcome of ankylosing spondylitis therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 973-981.	0.5	158
247	Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. <i>Rheumatology</i> , 2011, 50, 1690-1699.	0.9	105
248	Imaging of axial spondyloarthritis including ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, i97-i103.	0.5	61
249	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1369-1374.	0.5	293
250	Relation of HLA-B27, Tumor Necrosis Factor- β Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis—A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort. <i>Journal of Rheumatology</i> , 2011, 38, 2436-2441.	1.0	18
251	Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 799-804.	0.5	78
252	Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 755-759.	0.5	146

#	ARTICLE	IF	CITATIONS
253	OMERACT Magnetic Resonance Imaging Initiative on Structural and Inflammatory Lesions in Ankylosing Spondylitis – Report of a Special Interest Group at OMERACT 10 on Sacroiliac Joint and Spine Lesions. <i>Journal of Rheumatology</i> , 2011, 38, 2051-2054.	1.0	19
254	Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1108-1110.	0.5	152
255	A stratified model for health outcomes in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1758-1764.	0.5	65
256	ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 249-251.	0.5	208
257	Developing and validating an index for measuring health in patients with ankylosing spondylitis. <i>Rheumatology</i> , 2011, 50, 894-898.	0.9	18
258	Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2011, 3, 151-158.	1.2	35
259	Synovial Tissue Response to Treatment in Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2011, 5, 123-126.	0.1	2
260	The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 672-80.	0.4	41
261	Low-dose glucocorticoids in rheumatic diseases: introduction. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S2-4.	0.4	1
262	Glucocorticoid treatment in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S121-5.	0.4	8
263	Glucocorticoid treatment in spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S139-42.	0.4	10
264	Update on Biologic Therapy in the Management of Axial Spondyloarthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 325-331.	2.1	24
265	Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: Results from a randomized, placebo-controlled trial. <i>Arthritis Care and Research</i> , 2010, 62, 1266-1271.	1.5	50
266	Different response to rituximab in tumor necrosis factor blocker-naïve patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 1290-1297.	6.7	178
267	Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1465-1470.	0.5	244
268	A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1430-1435.	0.5	93
269	Quantifying Bone Marrow Edema in the Rheumatoid Cervical Spine Using Magnetic Resonance Imaging. <i>Journal of Rheumatology</i> , 2010, 37, 1626-1632.	1.0	10
270	ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 102-107.	0.5	93

#	ARTICLE	IF	CITATIONS
271	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, i2-i29.	0.5	113
272	Anti-TNF- α therapy with infliximab in spondyloarthritides. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 9-19.	1.3	16
273	Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1338-1341.	0.5	70
274	Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis. <i>Rheumatology</i> , 2010, 49, 1578-1589.	0.9	24
275	Hip involvement in ankylosing spondylitis. <i>Rheumatology</i> , 2010, 49, 3-4.	0.9	71
276	Spinal inflammation lesions as detected by magnetic resonance imaging in patients with early ankylosing spondylitis are more often observed in posterior structures of the spine. <i>Rheumatology</i> , 2010, 49, 749-755.	0.9	48
277	EULAR/EFORT recommendations for the diagnosis and initial management of patients with acute or recent onset swelling of the knee. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 12-19.	0.5	29
278	Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1264-1268.	0.5	71
279	Tolerability and Patient/Physician Satisfaction with Subcutaneously Administered Methotrexate Provided in Two Formulations of Different Drug Concentrations in Patients with Rheumatoid Arthritis–!2010-01-14–!2010-02-08–!2010-03-18–!. <i>Open Rheumatology Journal</i> , 2010, 4, 15-22.	0.1	21
280	Methotrexate–the anchor drug–an introduction. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S1-2.	0.4	3
281	Optimal administration and dosage of methotrexate. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S46-51.	0.4	5
282	Perioperative use of methotrexate. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S110-3.	0.4	4
283	Use of methotrexate in inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S164-7.	0.4	10
284	Use of methotrexate in patients with sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S183-5.	0.4	6
285	Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1520-1527.	0.5	719
286	ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1381-1386.	0.5	45
287	Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1334-1339.	0.5	45
288	The Natural Course of Radiographic Progression in Ankylosing Spondylitis “ Evidence for Major Individual Variations in a Large Proportion of Patients. <i>Journal of Rheumatology</i> , 2009, 36, 997-1002.	1.0	161

#	ARTICLE	IF	CITATIONS
289	Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 175-182.	0.5	122
290	Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: Addition of the thoracic spine improves sensitivity to change. <i>Arthritis and Rheumatism</i> , 2009, 61, 764-771.	6.7	72
291	The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort. <i>Arthritis and Rheumatism</i> , 2009, 60, 717-727.	6.7	605
292	Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. <i>Arthritis and Rheumatism</i> , 2009, 61, 1032-1036.	6.7	32
293	The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, ii1-ii44.	0.5	1,092
294	ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1811-1818.	0.5	491
295	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 770-776.	0.5	731
296	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 777-783.	0.5	2,713
297	Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: A methodological exploration. <i>Disability and Rehabilitation</i> , 2009, 31, 528-537.	0.9	32
298	Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 18-24.	0.5	772
299	Therapy of Spondyloarthritis. <i>Advances in Experimental Medicine and Biology</i> , 2009, 649, 133-147.	0.8	12
300	An update on methotrexate. <i>Current Opinion in Rheumatology</i> , 2009, 21, 216-223.	2.0	115
301	Treatment of ankylosing spondylitis and other spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 324-334.	2.0	30
302	Socioeconomic aspects of ankylosing spondylitis. , 2009, , 73-73.		0
303	A systematic comparison between rheumatoid arthritis and ankylosing spondylitis: an introduction. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S1-2.	0.4	21
304	Classification criteria for rheumatoid arthritis and ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S68-73.	0.4	6
305	Clinical measures in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S80-2.	0.4	2
306	Mortality in rheumatoid arthritis and ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S127-30.	0.4	24

#	ARTICLE	IF	CITATIONS
307	Treatment of rheumatoid arthritis and ankylosing spondylitis. Clinical and Experimental Rheumatology, 2009, 27, S146-7.	0.4	8
308	Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clinical and Experimental Rheumatology, 2009, 27, S164-7.	0.4	11
309	A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases. Clinical and Experimental Rheumatology, 2009, 27, S168-70.	0.4	0
310	Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis and Rheumatism, 2008, 58, 73-81.	6.7	298
311	Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. Arthritis and Rheumatism, 2008, 58, 649-656.	6.7	206
312	Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis and Rheumatism, 2008, 58, 1981-1991.	6.7	293
313	Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 58, 3063-3070.	6.7	461
314	Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis and Rheumatism, 2008, 58, 3402-3412.	6.7	512
315	Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis and Rheumatism, 2008, 59, 1270-1278.	6.7	98
316	T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis. Clinical and Experimental Immunology, 2008, 91, 96-102.	1.1	54
317	Analysis of cytokine profiles in synovial T cell clones from chlamydial reactive arthritis patients: predominance of the Th1 subset. Clinical and Experimental Immunology, 2008, 94, 122-126.	1.1	56
318	The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2008, 10, R104.	1.6	211
319	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Annals of the Rheumatic Diseases, 2008, 67, iii2-iii25.	0.5	99
320	Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Annals of the Rheumatic Diseases, 2008, 67, 511-517.	0.5	127
321	The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. Scandinavian Journal of Rheumatology, 2008, 37, 62-71.	0.6	18
322	Use of NSAIDs and infection with Helicobacter pylori-what does the rheumatologist need to know?. Rheumatology, 2008, 47, 1342-1347.	0.9	16
323	What is the most important outcome parameter in ankylosing spondylitis?. Rheumatology, 2008, 47, 1738-1740.	0.9	20
324	Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring: Figure 1. Annals of the Rheumatic Diseases, 2008, 67, 572-574.	0.5	32

#	ARTICLE	IF	CITATIONS
325	Canadian recommendations for the management of spondyloarthritis address many different levels of patient care. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 234-235.	3.2	0
326	Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 782-788.	0.5	31
327	New onset of Crohn's disease during treatment of active ankylosing spondylitis with etanercept. <i>Journal of Rheumatology</i> , 2008, 35, 532-6.	1.0	40
328	Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy. <i>Journal of Rheumatology</i> , 2008, 35, 1079-82.	1.0	17
329	Successful use of anakinra to treat refractory Schnitzler's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 354-7.	0.4	30
330	Neuromuscular involvement in rheumatic patients treated with anti-tumor necrosis factor therapy—three examples. <i>Journal of Rheumatology</i> , 2008, 35, 2074-6.	1.0	14
331	Mortality in ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, S80-4.	0.4	28
332	Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. <i>Rheumatology</i> , 2007, 46, 999-1004.	0.9	83
333	MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1276-1281.	0.5	243
334	Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 910-915.	0.5	237
335	Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 346-352.	0.5	140
336	Adalimumab for the treatment of ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 831-838.	0.9	18
337	Persistent clinical efficacy and safety of anti-tumour necrosis factor \hat{A} therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 340-345.	0.5	121
338	Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1218-1221.	0.5	50
339	Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF- \hat{A} antibody infliximab. <i>Rheumatology</i> , 2007, 46, 1450-1453.	0.9	169
340	Magnetic resonance imaging in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2007, 19, 346-352.	2.0	45
341	Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. <i>International Journal of Technology Assessment in Health Care</i> , 2007, 23, 368-375.	0.2	20
342	Ankylosing spondylitis. <i>Lancet</i> , The, 2007, 369, 1379-1390.	6.3	1,558

#	ARTICLE	IF	CITATIONS
343	The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2007, 9, R103.	1.6	39
344	Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor agents. <i>Arthritis and Rheumatism</i> , 2007, 57, 639-647.	6.7	177
345	Assessments in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 699-712.	1.4	33
346	Microvascular dysfunction in rheumatoid arthritis assessed by laser Doppler anemometry: relationship to soluble adhesion molecules and extraarticular manifestations. <i>Rheumatology International</i> , 2007, 28, 145-152.	1.5	13
347	Bildgebung bei Spondylitis ankylosans. , 2007, , 103-127.		1
348	Imaging in Reactive Arthritis. , 2007, , 195-199.		0
349	A comparative study of patient-reported functional outcomes in acute rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 64-9.	1.0	11
350	Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2007, 34, 510-5.	1.0	47
351	Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. <i>Journal of Rheumatology</i> , 2007, 34, 862-70.	1.0	97
352	Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?. <i>Journal of Rheumatology</i> , 2007, 34, 871-3.	1.0	31
353	Rheumatic manifestations of lymphoproliferative disorders. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 35-9.	0.4	2
354	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007, 34, 1733-9.	1.0	57
355	Identification of relevant functional issues for the care of patients with acute arthritis by health professionals, using the ICF framework and a multi-disciplinary focus group approach. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 354-60.	0.4	7
356	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	1.0	74
357	Quality indicators, guidelines and outcome measures in ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 147-52.	0.4	7
358	Anti-TNF agents in the treatment of psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 99-107.	1.4	16
359	ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 442-452.	0.5	571
360	Developments and current pharmacotherapeutic recommendations for ankylosing spondylitis. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 869-883.	0.9	3

#	ARTICLE	IF	CITATIONS
361	Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor α in three more advanced cases. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 713-720.	0.5	159
362	The high prevalence of infections and allergic symptoms in patients with ankylosing spondylitis is associated with clinical symptoms. <i>Clinical Rheumatology</i> , 2006, 25, 648-658.	1.0	14
363	Infection and work stress are potential triggers of ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2006, 25, 660-666.	1.0	23
364	Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. <i>Clinical Rheumatology</i> , 2006, 25, 794-800.	1.0	60
365	Systematic review of measures and their concepts used in published studies focusing on the treatment of acute inflammatory arthritis. <i>Clinical Rheumatology</i> , 2006, 25, 807-813.	1.0	16
366	Magnetic resonance imaging in spondyloarthropathies. <i>Joint Bone Spine</i> , 2006, 73, 1-3.	0.8	49
367	Concepts and epidemiology of spondyloarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 401-417.	1.4	196
368	Assessments in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2006, 20, 521-537.	1.4	61
369	Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 678-681.	6.7	150
370	Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria. <i>Arthritis and Rheumatism</i> , 2006, 54, 569-578.	6.7	472
371	Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1646-1652.	6.7	220
372	Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 2136-2146.	6.7	768
373	Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2006, 55, 569-574.	6.7	76
374	An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1620-1625.	0.5	43
375	Definition of disease duration in ankylosing spondylitis: reassessing the concept. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1518-1520.	0.5	27
376	Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 201-208.	0.5	45
377	Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 423-432.	0.5	188
378	Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1147-1153.	0.5	149

#	ARTICLE	IF	CITATIONS
379	Magnetic resonance imaging in ankylosing spondylitis. <i>Future Rheumatology</i> , 2006, 1, 423-431.	0.2	6
380	Early diagnosis of spondyloarthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 536-545.	3.2	26
381	Conventional radiography versus MRI: how best to diagnose early spondyloarthritis?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 526-527.	3.2	0
382	First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 316-320.	0.5	313
383	Biologic Therapies in Spondyloarthritis – The Current State. , 2006, , 169-185.		0
384	Identification of health problems in patients with acute inflammatory arthritis, using the International Classification of Functioning, Disability and Health (ICF). <i>Clinical and Experimental Rheumatology</i> , 2006, 24, 239-46.	0.4	9
385	Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. <i>Journal of Rheumatology</i> , 2006, 33, 2475-83.	1.0	68
386	Remission in ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, S-88-92.	0.4	10
387	Treatment of spondyloarthritis with anti-TNFalpha biologic agents. <i>Reumatismo</i> , 2006, 58 Spec No.1, 71-2.	0.4	0
388	Management and treatment of ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2005, 17, 418-425.	2.0	16
389	Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2005, 52, 386-394.	6.7	94
390	Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). <i>Arthritis and Rheumatism</i> , 2005, 52, 582-591.	6.7	773
391	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor ? receptor fusion protein etanercept. <i>Arthritis and Rheumatism</i> , 2005, 52, 1216-1223.	6.7	198
392	Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. <i>Arthritis and Rheumatism</i> , 2005, 52, 2447-2451.	6.7	385
393	Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. <i>Arthritis and Rheumatism</i> , 2005, 53, 856-863.	6.7	140
394	Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. <i>Rheumatology</i> , 2005, 44, 1525-1530.	0.9	141
395	The process of producing recommendations for rheumatic diseases: what is evidence?. <i>Annals of the Rheumatic Diseases</i> , 2005, 65, 979-979.	0.5	2
396	Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1557-1562.	0.5	155

#	ARTICLE	IF	CITATIONS
397	Six months open label trial of leflunomide in active ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 124-126.	0.5	121
398	Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 730-734.	0.5	158
399	Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1305-1310.	0.5	136
400	Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1141-1144.	0.5	129
401	ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, ii108-ii109.	0.5	4
402	Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 229-234.	0.5	137
403	Persistent clinical response to the anti-TNF- α antibody infliximab in patients with ankylosing spondylitis over 3 years. <i>Rheumatology</i> , 2005, 44, 670-676.	0.9	174
404	Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1462-1466.	0.5	176
405	Seronegative spondyloarthropathies: to lump or split?. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, ii9-ii13.	0.5	44
406	Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. <i>British Journal of Rheumatology</i> , 2005, 44, 342-348.	2.5	134
407	Therapy of ankylosing spondylitis – a review. Part I: Conventional medical treatment and surgical therapy. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 97-108.	0.6	38
408	Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 1644-1646.	0.5	53
409	Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides. <i>Scandinavian Journal of Rheumatology</i> , 2005, 34, 178-190.	0.6	48
410	The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. <i>Rheumatology</i> , 2005, 44, 1483-1491.	0.9	137
411	Lack of a difference in increased capillary blood cell velocity in the skin over proximal interphalangeal joints between rheumatoid arthritis and osteoarthritis. <i>Microvascular Research</i> , 2005, 70, 1-6.	1.1	5
412	Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. <i>Arthritis Research</i> , 2005, 7, R439.	2.0	233
413	Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. <i>Journal of Rheumatology</i> , 2005, 32, 1290-8.	1.0	110
414	Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. <i>Journal of Rheumatology</i> , 2005, 32, 1751-4.	1.0	54

#	ARTICLE	IF	CITATIONS
415	Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7. Journal of Rheumatology, 2005, 32, 2042-7.	1.0	37
416	Scoring sacroiliac joints by magnetic resonance imaging. A multiple-reader reliability experiment. Journal of Rheumatology, 2005, 32, 2050-5.	1.0	60
417	Magnetic resonance imaging of inflammatory lesions in the spine in ankylosing spondylitis clinical trials: is paramagnetic contrast medium necessary?. Journal of Rheumatology, 2005, 32, 2056-60.	1.0	56
418	Assessment of ankylosing spondylitis. Clinical and Experimental Rheumatology, 2005, 23, S133-41.	0.4	30
419	CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects. Clinical and Experimental Rheumatology, 2005, 23, 840-6.	0.4	3
420	The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R)). British Journal of Rheumatology, 2004, 43, 1158-1166.	2.5	97
421	Development and preselection of criteria for short term improvement after anti-TNF α treatment in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2004, 63, 1438-1444.	0.5	188
422	Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2004, 63, 665-670.	0.5	391
423	Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases, 2004, 63, 1670-1672.	0.5	51
424	Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Annals of the Rheumatic Diseases, 2004, 63, 1046-1055.	0.5	147
425	An elevated level of IL-10- and TGF β -secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Clinical Rheumatology, 2004, 23, 435-440.	1.0	33
426	Current Concepts in the Therapy of the Spondyloarthritides. BioDrugs, 2004, 18, 307-314.	2.2	6
427	Biological therapies in the spondyloarthritides--the current state. British Journal of Rheumatology, 2004, 43, 1072-1084.	2.5	89
428	How to diagnose axial spondyloarthritis early. Annals of the Rheumatic Diseases, 2004, 63, 535-543.	0.5	533
429	Expanding the armamentarium for the spondyloarthropathies. Arthritis Research, 2004, 6, S36.	2.0	6
430	Knochen-und Gelenkinfektionen. , 2004, , 640-652.		0
431	Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. Journal of Rheumatology, 2004, 31, 531-8.	1.0	65
432	Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatology International, 2003, 23, 61-66.	1.5	707

#	ARTICLE	IF	CITATIONS
433	Restrictive mitral annuloplasty in refractory cardiogenic shock with acute postinfarction mitral insufficiency and intact papillary muscle. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 284-286.	0.4	5
434	Electromagnetic actuator for generating variably oriented shear waves in MR elastography. <i>Magnetic Resonance in Medicine</i> , 2003, 50, 220-222.	1.9	29
435	Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. <i>Arthritis and Rheumatism</i> , 2003, 48, 780-790.	6.7	112
436	Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system. <i>Arthritis and Rheumatism</i> , 2003, 48, 1126-1136.	6.7	377
437	Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: A detailed analysis by contrast-enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2003, 48, 1374-1384.	6.7	145
438	Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1667-1675.	6.7	394
439	Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 2224-2233.	6.7	217
440	Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 3230-3236.	6.7	707
441	Role of Novel Biological Therapies in Psoriatic Arthritis. <i>BioDrugs</i> , 2003, 17, 187-199.	2.2	32
442	Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 215-221.	0.5	35
443	Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 141-168.	1.4	32
444	International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 817-824.	0.5	353
445	Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. <i>British Journal of Rheumatology</i> , 2003, 42, 846-855.	2.5	73
446	Treatment of active ankylosing spondylitis with pamidronate. <i>British Journal of Rheumatology</i> , 2003, 42, 1018-1020.	2.5	52
447	Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1097-1109.	1.9	29
448	Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1023-1024.	0.5	3
449	Biologic therapies in the spondyloarthritis: new opportunities, new challenges. <i>Current Opinion in Rheumatology</i> , 2003, 15, 394-407.	2.0	36
450	Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 561-564.	0.5	120

#	ARTICLE	IF	CITATIONS
451	Spondylitis ankylosans. , 2003, , 315-360.		2
452	Reaktive Arthritis. , 2003, , 361-376.		0
453	Staging of patients with ankylosing spondylitis: a preliminary proposal. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 19iii-23.	0.5	33
454	T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 473-474.	0.5	4
455	Ankylosing spondylitis: an overview. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 8iii-18.	0.5	496
456	Anti-tumour necrosis factor Å therapy for ankylosing spondylitis: international experience. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 51iii-60.	0.5	54
457	Feature-based, Automated Segmentation of Cerebral Infarct Patterns Using T 2- and Diffusion-weighted Imaging. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2002, 5, 411-420.	0.9	8
458	Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. <i>Rheumatology</i> , 2002, 41, 110-111.	0.9	5
459	Treatment trials in ankylosing spondylitis: current and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 24iii-32.	0.5	17
460	Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 61iii-67.	0.5	27
461	Atopic disorders in ankylosing spondylitis and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 968-974.	0.5	91
462	Wegener's Granulomatosis Presenting as Necrosis of the Left Mainstem Bronchus. <i>Asian Cardiovascular and Thoracic Annals</i> , 2002, 10, 277-279.	0.2	4
463	Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. <i>Arthritis Research</i> , 2002, 4, 307.	2.0	113
464	Anti-TNF agents for the treatment of spondyloarthropathies. <i>Expert Opinion on Emerging Drugs</i> , 2002, 7, 235-246.	1.0	13
465	Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. <i>Lancet, The</i> , 2002, 359, 1187-1193.	6.3	1,204
466	Ankylosing spondylitis and current disease-controlling agents: do they work?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 619-630.	1.4	4
467	Therapy for ankylosing spondylitis: new treatment modalities. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 631-651.	1.4	16
468	Imaging and scoring in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 573-604.	1.4	73

#	ARTICLE	IF	CITATIONS
469	Diagnosing reactive arthritis: Role of clinical setting in the value of serologic and microbiologic assays. <i>Arthritis and Rheumatism</i> , 2002, 46, 319-327.	6.7	120
470	Aktueller Stand der Therapieansätze bei Spondylarthropathien. , 2002, , 17-22.		0
471	Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. <i>Journal of Rheumatology</i> , 2002, 29, 118-22.	1.0	103
472	Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, 80-4.	0.4	6
473	Prevalence of spondyloarthropathy in Japan. <i>Journal of Rheumatology</i> , 2002, 29, 1105-7; author reply 1107.	1.0	33
474	Imaging and scoring in ankylosing spondylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 573-604.	1.4	30
475	Novel anti-rheumatic therapies challenge old views on ankylosing spondylitis and other spondyloarthritides. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S1-2.	0.4	0
476	Ankylosing spondylitis--cardiac manifestations. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S11-5.	0.4	91
477	Mortality, course of disease and prognosis of patients with ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S16-22.	0.4	69
478	Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S34-7.	0.4	25
479	Infliximab in the treatment of active and severe ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S106-10.	0.4	9
480	Side effects of anti-TNF therapy: current knowledge. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S152-7.	0.4	91
481	Bisphosphonates--targeting bone in the treatment of spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S162-6.	0.4	10
482	Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S167-74.	0.4	25
483	Imaging and scoring in ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S178-84.	0.4	31
484	Anti-TNF therapy and the spondyloarthritides: who should be treated?. <i>Clinical and Experimental Rheumatology</i> , 2002, 20, S187.	0.4	2
485	New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. <i>Current Opinion in Rheumatology</i> , 2001, 13, 245-249.	2.0	62
486	Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. <i>Current Opinion in Rheumatology</i> , 2001, 13, 255-264.	2.0	133

#	ARTICLE	IF	CITATIONS
487	Infliximab treatment of severe ankylosing spondylitis: One-year followup. <i>Arthritis and Rheumatism</i> , 2001, 44, 2936-2937.	6.7	76
488	Volume-selective proton MR spectroscopy for in-vitro quantification of anticonvulsants. <i>Neuroradiology</i> , 2001, 43, 211-217.	1.1	12
489	Low incidence of reactive arthritis in children following a salmonella outbreak. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1055-1057.	0.5	46
490	Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 337-343.	0.5	96
491	Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 36-42.	0.5	150
492	New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. <i>Annals of the Rheumatic Diseases</i> , 2001, 60 Suppl 3, iii58-61.	0.5	8
493	Imaging of Inflammatory Rheumatic Diseases of the Axial Skeleton (Sacroiliitis): When and How Should We Use MRI?. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 339-349.	0.5	4
494	Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. <i>Arthritis and Rheumatism</i> , 2000, 43, 1346-1352.	6.7	506
495	Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. <i>Arthritis and Rheumatism</i> , 2000, 43, 2834-2842.	6.7	75
496	MR imaging of septic sacroiliitis. <i>Skeletal Radiology</i> , 2000, 29, 439-446.	1.2	112
497	Detailed Analyses of Periarticular Osteoporosis in Rheumatoid Arthritis. <i>Osteoporosis International</i> , 2000, 11, 400-407.	1.3	71
498	Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 311-314.	0.5	66
499	Anti-TNFalpha : a new dimension in the pharmacotherapy of the spondyloarthropathies !?. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 404-407.	0.5	33
500	Multispecific CD4+ T Cell Response to a Single 12-mer Epitope of the Immunodominant Heat-Shock Protein 60 of <i>Yersinia enterocolitica</i> in <i>Yersinia</i> -Triggered Reactive Arthritis: Overlap with the B27-Restricted CD8 Epitope, Functional Properties, and Epitope Presentation by Multiple DR Alleles. <i>Journal of Immunology</i> , 2000, 164, 1529-1537.	0.4	55
501	Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha : first clinical and laboratory experiences. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 85i-89.	0.5	32
502	The possible role of myocardial biopsy in systemic sclerosis. <i>Rheumatology</i> , 2000, 39, 674-679.	0.9	39
503	Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis-- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , 2000, 59, 135-140.	0.5	303
504	Impact of sex on inheritance of ankylosing spondylitis. <i>Lancet</i> , The, 2000, 355, 1096-1097.	6.3	12

#	ARTICLE	IF	CITATIONS
505	Treatment of Reactive Arthritis. <i>BioDrugs</i> , 2000, 13, 21-28.	2.2	19
506	Imaging of sacroiliitis. <i>Clinical Rheumatology</i> , 2000, 19, 51-7.	1.0	141
507	Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. <i>Journal of Rheumatology</i> , 2000, 27, 613-22.	1.0	212
508	On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. <i>Journal of Rheumatology</i> , 2000, 27, 2185-92.	1.0	113
509	Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. <i>Rheumatology</i> , 1999, 38, 831-836.	0.9	99
510	The elevated ratio of interferon gamma-/ interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. <i>Rheumatology</i> , 1999, 38, 1058-1067.	0.9	73
511	The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. <i>British Journal of Rheumatology</i> , 1999, 38, 260-266.	2.5	102
512	Cytokines and the immunopathology of the spondyloarthropathies. <i>Current Rheumatology Reports</i> , 1999, 1, 67-77.	2.1	4
513	Iloprost treatment in systemic sclerosis: Comment on the concise communication by Tedeschi et al. <i>Arthritis and Rheumatism</i> , 1999, 42, 196-197.	6.7	2
514	No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: A three-month, multicenter, double-blind, randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 1999, 42, 1386-1396.	6.7	149
515	Low secretion of tumor necrosis factor γ , but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 2039-2044.	6.7	133
516	Spondyloarthropathy. <i>Lancet</i> , The, 1999, 353, 1526.	6.3	1
517	Rheumatologic manifestations of gastrointestinal disorders. <i>Current Opinion in Rheumatology</i> , 1999, 11, 68-74.	2.0	14
518	Reactive arthritis. <i>Current Opinion in Rheumatology</i> , 1999, 11, 238-243.	2.0	17
519	Problems and advances in the diagnosis of reactive arthritis. <i>Journal of Rheumatology</i> , 1999, 26, 1222-4.	1.0	23
520	The 19 kDa protein of <i>Yersinia enterocolitica</i> O:3 is recognized on the cellular and humoral level by patients with <i>Yersinia</i> induced reactive arthritis. <i>Journal of Rheumatology</i> , 1999, 26, 1964-71.	1.0	11
521	Sweet's syndrome in a patient with acute Crohn's colitis and longstanding ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 607-10.	0.4	12
522	Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. <i>Arthritis and Rheumatism</i> , 1998, 41, 58-67.	6.7	854

#	ARTICLE	IF	CITATIONS
523	Characterization of the synovial T cell response to various recombinant Yersinia antigens in Yersinia enterocolitica-triggered reactive arthritis: Heat-shock protein 60 drives a major immune response. Arthritis and Rheumatism, 1998, 41, 315-326.	6.7	89
524	Lack of correlation between the detection of Chlamydia trachomatis DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an antichlamydial immune response. Arthritis and Rheumatism, 1998, 41, 845-854.	6.7	77
525	Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1?: A case report. Arthritis and Rheumatism, 1998, 41, 1695-1701.	6.7	25
526	Use of contrast-enhanced MR imaging to detect sacroiliitis in children. Skeletal Radiology, 1998, 27, 606-616.	1.2	90
527	RADIOLOGIC DIAGNOSIS AND PATHOLOGY OF THE SPONDYLOARTHROPATHIES. Rheumatic Disease Clinics of North America, 1998, 24, 697-735.	0.8	173
528	Treatment of reactive arthritis with antibiotics. Rheumatology, 1998, 37, 717-720.	0.9	24
529	Longitudinal investigation of bacterium-specific synovial lymphocyte proliferation in reactive arthritis and lyme arthritis. Rheumatology, 1998, 37, 784-788.	0.9	10
530	Bacteria-specific lymphocyte proliferation in peripheral blood in reactive arthritis and related diseases. Rheumatology, 1998, 37, 520-524.	0.9	12
531	Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. , 1998, 41, 58.		9
532	T cell responses in reactive and Lyme arthritis. , 1998, , 169-187.		0
533	Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. Journal of Rheumatology, 1998, 25, 556-64.	1.0	71
534	Increased frequency of Sjögren's syndrome in patients with spondyloarthropathy. Journal of Rheumatology, 1998, 25, 718-24.	1.0	18
535	Short-term follow up of the Ross operation in children. Journal of Heart Valve Disease, 1998, 7, 615-9.	0.5	3
536	Comment on the article 'Reactive arthritis, beta-haemolytic Streptococcus and Staphylococcus aureus' by D. N. Leitch and C. D. Holland. Rheumatology, 1997, 36, 606-607.	0.9	1
537	IgA nephropathy in a patient with Behcet's syndrome--case report and review of literature. Rheumatology, 1997, 36, 696-699.	0.9	24
538	Normal morphology of sacroiliac joints in children: magnetic resonance studies related to age and sex. Skeletal Radiology, 1997, 26, 697-704.	1.2	59
539	Type II collagen serology: a guide to clinical responsiveness to oral tolerance?. Rheumatology International, 1997, 16, 237-240.	1.5	13
540	T cell cytokine pattern in the joints of patients with lyme arthritis and its regulation by cytokines and anticytokines. Arthritis and Rheumatism, 1997, 40, 69-79.	6.7	110

#	ARTICLE	IF	CITATIONS
541	Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. <i>Arthritis and Rheumatism</i> , 1997, 40, 945-954.	6.7	30
542	Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. <i>Arthritis and Rheumatism</i> , 1997, 40, 1788-1797.	6.7	158
543	Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. <i>Journal of Rheumatology</i> , 1997, 24, 1092-100.	1.0	50
544	Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. <i>Journal of Rheumatology</i> , 1997, 24, 1101-5.	1.0	40
545	A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. <i>Journal of Immunology</i> , 1997, 159, 5715-23.	0.4	81
546	Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. <i>Arthritis and Rheumatism</i> , 1996, 39, 41-51.	6.7	153
547	Commented glossary for rheumatic spinal diseases.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 76-78.	0.5	3
548	The sacroiliac joint in the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 1996, 8, 275-287.	2.0	120
549	CT-Guided Intraarticular Corticosteroid Injection into the Sacroiliac Joints in Patients with Spondyloarthropathy: Indication and Follow-Up with Contrast-Enhanced MRI. <i>Journal of Computer Assisted Tomography</i> , 1996, 20, 512-521.	0.5	119
550	Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. <i>Journal of Rheumatology</i> , 1996, 23, 659-64.	1.0	135
551	Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1995, 38, 499-505.	6.7	647
552	Pathogenesis of spondylarthropathies. <i>Arthritis and Rheumatism</i> , 1995, 38, 1547-1554.	6.7	175
553	Stapled ileal pouch-anal anastomosis with resection of the anal transition zone. <i>International Journal of Colorectal Disease</i> , 1995, 10, 142-147.	1.0	17
554	Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging.. <i>Radiology</i> , 1995, 194, 529-536.	3.6	201
555	The Evolutionarily Conserved Ribosomal Protein L23 and the Cationic Urease β -Subunit of Yersinia enterocolitica O:3 Belong to the Immunodominant Antigens in Yersinia-Triggered Reactive Arthritis: Implications for Autoimmunity. <i>Molecular Medicine</i> , 1994, 1, 44-55.	1.9	35
556	Chlamydia pneumoniae--a new causative agent of reactive arthritis and undifferentiated oligoarthritis.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 100-105.	0.5	134
557	Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. <i>Arthritis and Rheumatism</i> , 1994, 37, 1039-1045.	6.7	320
558	The evolutionarily conserved ribosomal protein L23 and the cationic urease beta-subunit of Yersinia enterocolitica O:3 belong to the immunodominant antigens in Yersinia-triggered reactive arthritis: implications for autoimmunity. <i>Molecular Medicine</i> , 1994, 1, 44-55.	1.9	8

#	ARTICLE	IF	CITATIONS
559	The specific antibacterial proliferation of reactive arthritis synovial T cells is not due to their higher proportion of CD45RO+ cells compared to peripheral blood. <i>Journal of Rheumatology</i> , 1994, 21, 1702-7.	1.0	6
560	Three-colour flowcytometric examination of CD4/CD45 subsets reveals no differences in peripheral blood and synovial fluid between patients with reactive arthritis and rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 1994, 12, 17-22.	0.4	9
561	Widespread vasculopathy with hemolytic uremic syndrome, perimyocarditis and cystic pancreatitis in a young woman with mixed connective tissue disease. <i>Rheumatology International</i> , 1993, 13, 31-36.	1.5	24
562	The value of specific antibody detection and culture in the diagnosis of reactive arthritis. <i>Clinical Rheumatology</i> , 1993, 12, 245-252.	1.0	19
563	THE POSSIBLE ROLE OF SHIGELLA IN SPORADIC ENTERIC REACTIVE ARTHRITIS. <i>Rheumatology</i> , 1993, 32, 582-585.	0.9	20
564	Erregerspezifische T-Zellen in der Synovialflüssigkeit bei infektassozierten Arthritiden. , 1993, , 212-218.		0
565	Aetiological role of bacteria associated with reactive arthritis in pauciarticular juvenile chronic arthritis.. <i>Annals of the Rheumatic Diseases</i> , 1992, 51, 1208-1214.	0.5	35
566	Results of intersphincteric resection of the rectum with direct coloanal anastomosis for rectal carcinoma. <i>American Journal of Surgery</i> , 1992, 163, 407-412.	0.9	104
567	Alteration in T Cell/Macrophage Ratio may Reveal Lymphocyte Proliferation Specific for the Triggering Antigen in Reactive Arthritis. <i>Scandinavian Journal of Immunology</i> , 1992, 36, 427-434.	1.3	6
568	Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. <i>Journal of Rheumatology</i> , 1992, 19, 1236-42.	1.0	47
569	Anal sphincter function after intersphincteric resection and stapled ileal pouch-anal anastomosis. <i>Diseases of the Colon and Rectum</i> , 1991, 34, 8-16.	0.7	35
570	Visceral Leishmaniasis mimicking a flare of systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 1991, 10, 445-448.	1.0	26
571	Severe Lupus Crisis with Agranulocytosis and Anuric Renal failure due to a Mesangial Lesion (WHO) Tj ETQq1 1 0.784314 rgBT /Overload 1991, 30, 312-313.	0.9	6